• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:RLFTY)

2.820 UNCHANGED
Streaming Delayed Price Updated: 11:56 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about RLFTY

< Previous 1 2 3 4 5 Next >
News headline image
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
December 23, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
December 15, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
November 14, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
October 29, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Publishes 2025 Half-Year Report
August 14, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
December 16, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
December 13, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Advances Publication of 2025 Half-Year Report
August 11, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
July 29, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
June 20, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces Results of Annual General Meeting
June 12, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
May 22, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
August 29, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Secures up to $11 Million from Royalty Sales
August 04, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
May 15, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
April 10, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
March 06, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
February 11, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
January 22, 2025
Via ACCESS Newswire
News headline image
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
December 27, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
November 10, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
November 03, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
October 28, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
October 24, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
October 20, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
October 07, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
October 03, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
September 17, 2024
Via ACCESSWIRE
News headline image
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
September 01, 2024
Via ACCESSWIRE
News headline image
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
June 27, 2024
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap